| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/00365520310006748 |
| P698 | PubMed publication ID | 15000272 |
| P2093 | author name string | Wagner A | |
| Jones J | |||
| Holme I | |||
| Nyhlin H | |||
| Bang C | |||
| Elsborg L | |||
| Silvennoinen J | |||
| Rüegg P | |||
| P2860 | cites work | 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine | Q45112735 |
| Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome | Q32054460 | ||
| Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome | Q33425798 | ||
| Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome | Q34768534 | ||
| An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome | Q35595584 | ||
| Irritable bowel syndrome in the general population | Q35819583 | ||
| A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation | Q39401938 | ||
| P433 | issue | 2 | |
| P921 | main subject | patient | Q181600 |
| placebo | Q269829 | ||
| P304 | page(s) | 119-126 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Scandinavian Journal of Gastroenterology | Q7429960 |
| P1476 | title | A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome | |
| P478 | volume | 39 |
| Q35597981 | A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation |
| Q45129525 | A response to Farup and Bytzer. Tegaserod Nordic trial |
| Q37253528 | Adequate relief in a treatment trial with IBS patients: a prospective assessment |
| Q43439726 | Adverse events appear to unblind clinical trials in irritable bowel syndrome |
| Q35681391 | Benefits from long-term treatment in irritable bowel syndrome |
| Q37164063 | Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles |
| Q50787299 | Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. |
| Q33435562 | Current gut-directed therapies for irritable bowel syndrome |
| Q36787468 | Current trends in migraine prophylaxis |
| Q51751566 | Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial. |
| Q36478089 | Drugs acting on serotonin receptors for the treatment of functional GI disorders |
| Q42738877 | Editorial: is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome? |
| Q46879620 | Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome |
| Q39331829 | Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. |
| Q37496549 | Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis |
| Q39885291 | Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design |
| Q46613363 | Expression and function of 5-HT4 receptors in the mouse enteric nervous system |
| Q34473834 | Genetics and pharmacogenetics of aminergic transmitter pathways in functional gastrointestinal disorders. |
| Q36779337 | IBS--review and what's new. |
| Q33695487 | Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation |
| Q39372719 | Meta-analysis: The treatment of irritable bowel syndrome |
| Q36173352 | Moxibustion treatment for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial |
| Q84617472 | Non-absorbed antibiotic for irritable bowel syndrome |
| Q35691226 | Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air? |
| Q33451900 | Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome |
| Q84345502 | Post-infectious irritable bowel syndrome |
| Q33958853 | Recent advances in pharmacological treatment of irritable bowel syndrome |
| Q38914226 | Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials. |
| Q39353092 | Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement |
| Q89835976 | Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications |
| Q37827564 | Review article: endpoints used in functional dyspepsia drug therapy trials |
| Q34650033 | Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility |
| Q35936942 | Review article: tegaserod -- the global experience |
| Q35925555 | Review of tegaserod in the treatment of irritable bowel syndrome |
| Q36931162 | Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation |
| Q36822923 | Serotonin receptor modulators in the treatment of irritable bowel syndrome. |
| Q33661852 | Studying sex and gender differences in pain and analgesia: a consensus report. |
| Q36536707 | Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective |
| Q36536709 | Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective |
| Q33436477 | Tegaserod for constipation-predominant irritable bowel syndrome |
| Q39319919 | Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial |
| Q90094143 | Tegaserod for the Treatment of Irritable Bowel Syndrome |
| Q24242922 | Tegaserod for the treatment of irritable bowel syndrome and chronic constipation |
| Q35919167 | Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom |
| Q43267055 | Tegaserod in the treatment of irritable bowel syndrome with constipation |
| Q46604896 | Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care |
| Q39337639 | The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients |
| Q33890463 | The effect of tegaserod on symptoms and quality of life in korean women with irritable bowel syndrome with constipation |
| Q33431815 | The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. |
| Q34409009 | The treatment of irritable bowel syndrome |
| Q37134572 | The trials and tribulations of drug development for functional gastrointestinal disorders |
| Q37156627 | Updates on treatment of irritable bowel syndrome |
| Q36995947 | Use of Serotonergic Drugs in Canada for Gastrointestinal Motility Disorders: Results of a Retrospective Cohort Study. |
| Q80307346 | [Drug therapy for irritable bowel syndrome. What works, what doesn't work and for whom?] |
Search more.